Full Publications

Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.Leveille E, Kothari S, Cosgun KN, Mlynarczyk C, Müschen M. Cancer Discov. 2024 Sep 4. PMID: 39228298.
Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery.Chan AKN, Han L, Delaney CD, Wang X, Mukhaleva E, Li M, Yang L, Pokharel SP, Mattson N, Garcia M, Wang B, Xu X, Zhang L, Singh P, Elsayed Z, Chen R, Kuang B, Wang J, Yuan YC, Chen B, Chan LN, Rosen ST, Horne D, Müschen M, Chen J, Vaidehi N, Armstrong SA, Su R, Chen CW. Sci Adv. 2024 Feb 23; 2024 Feb 23. PMID: 38394203.
Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression.Ecker V, Brandmeier L, Stumpf M, Giansanti P, Moreira AV, Pfeuffer L, Fens MHAM, Lu J, Kuster B, Engleitner T, Heidegger S, Rad R, Ringshausen I, Zenz T, Wendtner CM, Müschen M, Jellusova J, Ruland J, Buchner M. Cell Rep. 2023 Oct 31; 2023 Oct 4. PMID: 37792532.
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma.Wartewig T, Daniels J, Schulz M, Hameister E, Joshi A, Park J, Morrish E, Venkatasubramani AV, Cernilogar FM, van Heijster FHA, Hundshammer C, Schneider H, Konstantinidis F, Gabler JV, Klement C, Kurniawan H, Law C, Lee Y, Choi S, Guitart J, Forne I, Giustinani J, Müschen M, Jain S, Weinstock DM, Rad R, Ortonne N, Schilling F, Schotta G, Imhof A, Brenner D, Choi J, Ruland J. Nat Cancer. 2023 Oct; 2023 Sep 18. PMID: 37723306.
Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis.Li M, Yang L, Chan AKN, Pokharel SP, Liu Q, Mattson N, Xu X, Chang WH, Miyashita K, Singh P, Zhang L, Li M, Wu J, Wang J, Chen B, Chan LN, Lee J, Zhang XH, Rosen ST, Müschen M, Qi J, Chen J, Hiom K, Bishop AJR, Chen CW. Adv Sci (Weinh). 2023 Jun; 2023 Apr 19. PMID: 37075745.
Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia.Ogana HA, Hurwitz S, Hsieh CL, Geng H, Müschen M, Bhojwani D, Wolf MA, Larocque J, Lieber MR, Kim YM. Front Cell Dev Biol. 2023; 2023 Mar 31. PMID: 37082620.
Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia.Chen Z, Zhou K, Xue J, Small A, Xiao G, Nguyen LXT, Zhang Z, Prince E, Weng H, Huang H, Zhao Z, Qing Y, Shen C, Li W, Han L, Tan B, Su R, Qin H, Li Y, Wu D, Gu Z, Ngo VN, He X, Chao J, Leung K, Wang K, Dong L, Qin X, Cai Z, Sheng Y, Chen Y, Wu X, Zhang B, Shi Y, Marcucci G, Qian Z, Xu M, Müschen M, Chen J, Deng X. Sci Transl Med. 2023 Mar 29; 2023 Mar 29. PMID: 36989375.
Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms.Taghi Khani A, Kumar A, Sanchez Ortiz A, Radecki KC, Aramburo S, Lee SJ, Hu Z, Damirchi B, Lorenson MY, Wu X, Gu Z, Stohl W, Sanz I, Meffre E, Müschen M, Forman SJ, Koff JL, Walker AM, Swaminathan S. Commun Biol. 2023 Mar 20; 2023 Mar 20. PMID: 36941341.
Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignancies.Cosgun KN, Jumaa H, Robinson ME, Kistner KM, Xu L, Xiao G, Chan LN, Lee J, Kume K, Leveille E, Fonseca-Arce D, Khanduja D, Ng HL, Feldhahn N, Song J, Chan WC, Chen J, Taketo MM, Kothari S, Davids MS, Schjerven H, Jellusova J, Müschen M. bioRxiv. 2023 Mar 15; 2023 Mar 15. PMID: 36993619.
Dynamic phosphatase-recruitment controls B-cell selection and oncogenic signaling.Lee J, Robinson ME, Sun R, Kume K, Ma N, Cosgun KN, Chan LN, Leveille E, Geng H, Vykunta VS, Shy BR, Marson A, Katz S, Chen J, Paietta E, Meffre E, Vaidehi N, Müschen M. bioRxiv. 2023 Mar 15; 2023 Mar 15. PMID: 36993276.
Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling.Feng X, Sun R, Lee M, Chen X, Guo S, Geng H, Müschen M, Choi J, Pereira JP. Elife. 2023 Mar 13; 2023 Mar 13. PMID: 36912771.
Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies.Leveille E, Kothari S, Müschen M. Blood Cancer Discov. 2023 Jan 6. PMID: 36534735.
ACTR5 controls CDKN2A and tumor progression in an INO80-independent manner.Xu X, Chan AKN, Li M, Liu Q, Mattson N, Pangeni Pokharel S, Chang WH, Yuan YC, Wang J, Moore RE, Pirrotte P, Wu J, Su R, Müschen M, Rosen ST, Chen J, Yang L, Chen CW. Sci Adv. 2022 Dec 23; 2022 Dec 23. PMID: 36563143.
SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies.Leveille E, Chan LN, Mirza AS, Kume K, Müschen M. Cell Signal. 2022 Jun; 2022 Apr 7. PMID: 35398488.
Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Muschen M, Tissot FLH, Miser J, Kovach JS, Sattler M, Batra SK, Kulkarni P, Salgia R. Mol Cancer Ther. 2022 Apr 1. PMID: 35373301.
An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia.Geron I, Savino AM, Fishman H, Tal N, Brown J, Turati VA, James C, Sarno J, Hameiri-Grossman M, Lee YN, Rein A, Maniriho H, Birger Y, Zemlyansky A, Muler I, Davis KL, Marcu-Malina V, Mattson N, Parnas O, Wagener R, Fischer U, Barata JT, Jamieson CHM, Müschen M, Chen CW, Borkhardt A, Kirsch IR, Nagler A, Enver T, Izraeli S. Nat Commun. 2022 Feb 3; 2022 Feb 3. PMID: 35115489.
CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia.Ketzer F, Abdelrasoul H, Vogel M, Marienfeld R, Müschen M, Jumaa H, Wirth T, Ushmorov A. Oncogenesis. 2022 Jan 10; 2022 Jan 10. PMID: 35013097.
Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses.Contreras-Trujillo H, Eerdeng J, Akre S, Jiang D, Contreras J, Gala B, Vergel-Rodriguez MC, Lee Y, Jorapur A, Andreasian A, Harton L, Bramlett CS, Nogalska A, Xiao G, Lee JW, Chan LN, Müschen M, Merchant AA, Lu R. Nat Commun. 2021 Nov 11; 2021 Nov 11. PMID: 34764253.
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Muschen M, Tissot FLH, Miser J, Kovach JS, Sattler M, Batra SK, Kulkarni P, Salgia R. Mol Cancer Ther. 2021 Oct; 2021 Jul 12. PMID: 34253596.
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.Chan TY, Egbert CM, Maxson JE, Siddiqui A, Larsen LJ, Kohler K, Balasooriya ER, Pennington KL, Tsang TM, Frey M, Soderblom EJ, Geng H, Müschen M, Forostyan TV, Free S, Mercenne G, Banks CJ, Valdoz J, Whatcott CJ, Foulks JM, Bearss DJ, O'Hare T, Huang DCS, Christensen KA, Moody J, Warner SL, Tyner JW, Andersen JL. Nat Commun. 2021 Sep 9; 2021 Sep 9. PMID: 34504101.
High-resolution characterization of gene function using single-cell CRISPR tiling screen.Yang L, Chan AKN, Miyashita K, Delaney CD, Wang X, Li H, Pokharel SP, Li S, Li M, Xu X, Lu W, Liu Q, Mattson N, Chen KY, Wang J, Yuan YC, Horne D, Rosen ST, Soto-Feliciano Y, Feng Z, Hoshii T, Xiao G, Müschen M, Chen J, Armstrong SA, Chen CW. Nat Commun. 2021 Jul 1; 2021 Jul 1. PMID: 34210975.
Metabolic determinants of B-cell selection.Chan LN, Aghania E, Leveille E, Müschen M. Biochem Soc Trans. 2021 Jun 30. PMID: 34196360.
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia.Ecker V, Stumpf M, Brandmeier L, Neumayer T, Pfeuffer L, Engleitner T, Ringshausen I, Nelson N, Jücker M, Wanninger S, Zenz T, Wendtner C, Manske K, Steiger K, Rad R, Müschen M, Ruland J, Buchner M. Nat Commun. 2021 Jun 10; 2021 Jun 10. PMID: 34112805.
Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.Sadras T, Martin M, Kume K, Robinson ME, Saravanakumar S, Lenz G, Chen Z, Song JY, Siddiqi T, Oksa L, Knapp AM, Cutler J, Cosgun KN, Klemm L, Ecker V, Winchester J, Ghergus D, Soulas-Sprauel P, Kiefer F, Heisterkamp N, Pandey A, Ngo V, Wang L, Jumaa H, Buchner M, Ruland J, Chan WC, Meffre E, Martin T, Müschen M. Mol Cell. 2021 May 20; 2021 Apr 19. PMID: 33878293.
Topography of transcriptionally active chromatin in glioblastoma.Xu L, Chen Y, Huang Y, Sandanaraj E, Yu JS, Lin RY, Dakle P, Ke XY, Chong YK, Koh L, Mayakonda A, Nacro K, Hill J, Huang ML, Gery S, Lim SW, Huang Z, Xu Y, Chen J, Bai L, Wang S, Wakimoto H, Yeo TT, Ang BT, Müschen M, Tang C, Tan TZ, Koeffler HP. Sci Adv. 2021 Apr; 2021 Apr 30. PMID: 33931443.
Author Correction: IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.Lee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, Nix MA, Klemm L, Chen CW, Chen J, Khairnar V, Wiita AP, Thomas-Tikhonenko A, Farzan M, Jung JU, Weinstock DM, Manalis SR, Diamond MS, Vaidehi N, Müschen M. Nature. 2021 Apr. PMID: 33712811.
R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m(6)A/PFKP/LDHB axis.Qing Y, Dong L, Gao L, Li C, Li Y, Han L, Prince E, Tan B, Deng X, Wetzel C, Shen C, Gao M, Chen Z, Li W, Zhang B, Braas D, Ten Hoeve J, Sanchez GJ, Chen H, Chan LN, Chen CW, Ann D, Jiang L, Müschen M, Marcucci G, Plas DR, Li Z, Su R, Chen J. Mol Cell. 2021 Mar 4. PMID: 33434505.
PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis.Pan L, Hong C, Chan LN, Xiao G, Malvi P, Robinson ME, Geng H, Reddy ST, Lee J, Khairnar V, Cosgun KN, Xu L, Kume K, Sadras T, Wang S, Wajapeyee N, Müschen M. Proc Natl Acad Sci U S A. 2021 Feb 16. PMID: 33531346.
Metabolic Gatekeepers of Pathological B Cell Activation.Sadras T, Chan LN, Xiao G, Müschen M. Annu Rev Pathol. 2021 Jan 24; 2020 Dec 15. PMID: 33321055.
IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.Lee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, Nix MA, Klemm L, Chen CW, Chen J, Khairnar V, Wiita AP, Thomas-Tikhonenko A, Farzan M, Jung JU, Weinstock DM, Manalis SR, Diamond MS, Vaidehi N, Müschen M. Nature. 2020 Dec; 2020 Nov 4. PMID: 33149299.
Core transcriptional regulatory circuitries in cancer.Chen Y, Xu L, Lin RY, Müschen M, Koeffler HP. Oncogene. 2020 Oct; 2020 Sep 17. PMID: 32943730.
IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.Song C, Ge Z, Ding Y, Tan BH, Desai D, Gowda K, Amin S, Gowda R, Robertson GP, Yue F, Huang S, Spiegelman V, Payne JL, Reeves ME, Gurel Z, Iyer S, Dhanyamraju PK, Xiang M, Kawasawa YI, Cury NM, Yunes JA, McGrath M, Schramm J, Su R, Yang Y, Zhao Z, Lyu X, Muschen M, Payne KJ, Gowda C, Dovat S. Blood. 2020 Sep 24. PMID: 32396934.
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L, Li C, Zhao Z, Robinson S, Tan B, Qing Y, Qin X, Prince E, Xie J, Qin H, Li W, Shen C, Sun J, Kulkarni P, Weng H, Huang H, Chen Z, Zhang B, Wu X, Olsen MJ, Müschen M, Marcucci G, Salgia R, Li L, Fathi AT, Li Z, Mulloy JC, Wei M, Horne D, Chen J. Cancer Cell. 2020 Jul 13; 2020 Jun 11. PMID: 32531268.
Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.Gang EJ, Kim HN, Hsieh YT, Ruan Y, Ogana HA, Lee S, Pham J, Geng H, Park E, Klemm L, Willman CL, Carroll WL, Mittelman SD, Orgel E, Oberley MJ, Parekh C, Abdel-Azim H, Bhojwani D, Wayne AS, De Arcangelis A, Georges-Labouesse E, Wayner E, Bonig H, Minasyan A, Ten Hoeve J, Graeber TG, Müschen M, Heisterkamp N, Kim YM. Blood. 2020 Jul 9. PMID: 32219444.
MEF2D Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL.Sadras T, Müschen M. Blood Cancer Discov. 2020 Jul; 2020 Jun 22. PMID: 34661138.
Signalling input from divergent pathways subverts B cell transformation.Chan LN, Murakami MA, Robinson ME, Caeser R, Sadras T, Lee J, Cosgun KN, Kume K, Khairnar V, Xiao G, Ahmed MA, Aghania E, Deb G, Hurtz C, Shojaee S, Hong C, Pölönen P, Nix MA, Chen Z, Chen CW, Chen J, Vogt A, Heinäniemi M, Lohi O, Wiita AP, Izraeli S, Geng H, Weinstock DM, Müschen M. Nature. 2020 Jul; 2020 Jul 22. PMID: 32699415.
Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.Abdelrasoul H, Vadakumchery A, Werner M, Lenk L, Khadour A, Young M, El Ayoubi O, Vogiatzi F, Krämer M, Schmid V, Chen Z, Yousafzai Y, Cario G, Schrappe M, Müschen M, Halsey C, Mulaw MA, Schewe DM, Hobeika E, Alsadeq A, Jumaa H. Nat Commun. 2020 Jun 24; 2020 Jun 24. PMID: 32581241.
CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1(T315I) mutation mouse model.Tan YT, Ye L, Xie F, Wang J, Müschen M, Chen SJ, Kan YW, Liu H. Haematologica. 2020 May; 2019 Sep 19. PMID: 31537693.
Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion.Xiu Y, Dong Q, Fu L, Bossler A, Tang X, Boyce B, Borcherding N, Leidinger M, Sardina JL, Xue HH, Li Q, Feldman A, Aifantis I, Boccalatte F, Wang L, Jin M, Khoury J, Wang W, Hu S, Yuan Y, Wang E, Yuan J, Janz S, Colgan J, Habelhah H, Waldschmidt T, Müschen M, Bagg A, Darbro B, Zhao C. Blood. 2020 Jan 9. PMID: 31697816.
Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID.Rodríguez-Hernández G, Opitz FV, Delgado P, Walter C, Álvarez-Prado ÁF, González-Herrero I, Auer F, Fischer U, Janssen S, Bartenhagen C, Raboso-Gallego J, Casado-García A, Orfao A, Blanco O, Alonso-López D, Rivas JL, Tena-Dávila SG, Müschen M, Dugas M, Criado FJG, Cenador MBG, Vicente-Dueñas C, Hauer J, Ramiro AR, Sanchez-Garcia I, Borkhardt A. Nat Commun. 2019 Dec 5; 2019 Dec 5. PMID: 31804490.
Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.Zhu Y, He X, Lin YC, Dong H, Zhang L, Chen X, Wang Z, Shen Y, Li M, Wang H, Sun J, Nguyen LX, Zhang H, Jiang W, Yang Y, Chen J, Müschen M, Chen CW, Konopleva MY, Sun W, Jin J, Carlesso N, Marcucci G, Luo Y, Li L. Blood. 2019 Oct 10. PMID: 31395602.
Origins of the human B-cell lineage.Müschen M. Blood. 2019 Sep 26. PMID: 31558555.
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW. Sci Transl Med. 2019 Sep 25. PMID: 31554741.
Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia.Hurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Chen CW, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M. Genes Dev. 2019 Sep 1; 2019 Aug 8. PMID: 31395741.
Chemical choreography of germinal center B-cell migration.Ngo VN, Müschen M. Cell Res. 2019 Jul. PMID: 31024167.
Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation.Müschen M. Nat Rev Immunol. 2019 May. PMID: 30890785.
Histone H3 trimethylation at lysine 36 guides m(6)A RNA modification co-transcriptionally.Huang H, Weng H, Zhou K, Wu T, Zhao BS, Sun M, Chen Z, Deng X, Xiao G, Auer F, Klemm L, Wu H, Zuo Z, Qin X, Dong Y, Zhou Y, Qin H, Tao S, Du J, Liu J, Lu Z, Yin H, Mesquita A, Yuan CL, Hu YC, Sun W, Su R, Dong L, Shen C, Li C, Qing Y, Jiang X, Wu X, Sun M, Guan JL, Qu L, Wei M, Müschen M, Huang G, He C, Yang J, Chen J. Nature. 2019 Mar; 2019 Mar 13. PMID: 30867593.
Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, Mei M, Popplewell L, Pham LV, Kwak LW, Weisenburger DD, Rosen ST, Chan WC, Müschen M, Ngo VN. Blood. 2019 Jan 24; 2018 Dec 10. PMID: 30530749.
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T. Cell Rep. 2018 Jun 12. PMID: 29898385.
Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors.Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M. Nature. 2018 Jun. PMID: 29849140.
Loss of Pax5 Exploits Sca1-BCR-ABL(p190) Susceptibility to Confer the Metabolic Shift Essential for pB-ALL.Martín-Lorenzo A, Auer F, Chan LN, García-Ramírez I, González-Herrero I, Rodríguez-Hernández G, Bartenhagen C, Dugas M, Gombert M, Ginzel S, Blanco O, Orfao A, Alonso-López D, Rivas JL, García-Cenador MB, García-Criado FJ, Müschen M, Sánchez-García I, Borkhardt A, Vicente-Dueñas C, Hauer J. Cancer Res. 2018 May 15; 2018 Feb 28. PMID: 29490943.
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M. Cell. 2018 Apr 5; 2018 Mar 15. PMID: 29551267.
Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies.Pollock SB, Hu A, Mou Y, Martinko AJ, Julien O, Hornsby M, Ploder L, Adams JJ, Geng H, Müschen M, Sidhu SS, Moffat J, Wells JA. Proc Natl Acad Sci U S A. 2018 Mar 13; 2018 Feb 23. PMID: 29476010.
Targeting the vulnerability to NAD(+) depletion in B-cell acute lymphoblastic leukemia.Takao S, Chien W, Madan V, Lin DC, Ding LW, Sun QY, Mayakonda A, Sudo M, Xu L, Chen Y, Jiang YY, Gery S, Lill M, Park E, Senapedis W, Baloglu E, Müschen M, Koeffler HP. Leukemia. 2018 Mar; 2017 Sep 14. PMID: 28904384.
CAMKs support development of acute myeloid leukemia.Kang X, Cui C, Wang C, Wu G, Chen H, Lu Z, Chen X, Wang L, Huang J, Geng H, Zhao M, Chen Z, Müschen M, Wang HY, Zhang CC. J Hematol Oncol. 2018 Feb 27; 2018 Feb 27. PMID: 29482582.
Autoimmunity checkpoints as therapeutic targets in B cell malignancies.Müschen M. Nat Rev Cancer. 2018 Feb; 2018 Jan 5. PMID: 29302068.
Portending death in germinal centers - when B cells know their time is up.Wang L, Müschen M. Cell Res. 2018 Jan; 2017 Dec 1. PMID: 29192678.
Circadian clock cryptochrome proteins regulate autoimmunity.Cao Q, Zhao X, Bai J, Gery S, Sun H, Lin DC, Chen Q, Chen Z, Mack L, Yang H, Deng R, Shi X, Chong LW, Cho H, Xie J, Li QZ, Müschen M, Atkins AR, Liddle C, Yu RT, Alkan S, Said JW, Zheng Y, Downes M, Evans RM, Koeffler HP. Proc Natl Acad Sci U S A. 2017 Nov 21; 2017 Nov 6. PMID: 29109286.
Extrafollicular CD4(+) T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease.Deng R, Hurtz C, Song Q, Yue C, Xiao G, Yu H, Wu X, Muschen M, Forman S, Martin PJ, Zeng D. Nat Commun. 2017 Oct 17; 2017 Oct 17. PMID: 29042531.
Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia.Gugliotta G, Sudo M, Cao Q, Lin DC, Sun H, Takao S, Le Moigne R, Rolfe M, Gery S, Müschen M, Cavo M, Koeffler HP. Neoplasia. 2017 Oct; 2017 Aug 29. PMID: 28843399.
Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.Sun H, Lin DC, Guo X, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP. Oncotarget. 2017 Sep 8; 2017 Sep 8. PMID: 28969101.
B-cell identity as a metabolic barrier against malignant transformation.Chan LN, Müschen M. Exp Hematol. 2017 Sep; 2017 Jun 24. PMID: 28655536.
mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph(+) and Ph-like B-ALL.Vo TT, Lee JS, Nguyen D, Lui B, Pandori W, Khaw A, Mallya S, Lu M, Müschen M, Konopleva M, Fruman DA. Mol Cancer Ther. 2017 Sep; 2017 May 31. PMID: 28566433.
Infection Exposure Promotes ETV6-RUNX1 Precursor B-cell Leukemia via Impaired H3K4 Demethylases.Rodríguez-Hernández G, Hauer J, Martín-Lorenzo A, Schäfer D, Bartenhagen C, García-Ramírez I, Auer F, González-Herrero I, Ruiz-Roca L, Gombert M, Okpanyi V, Fischer U, Chen C, Dugas M, Bhatia S, Linka RM, Garcia-Suquia M, Rascón-Trincado MV, Garcia-Sanchez A, Blanco O, García-Cenador MB, García-Criado FJ, Cobaleda C, Alonso-López D, De Las Rivas J, Müschen M, Vicente-Dueñas C, Sánchez-García I, Borkhardt A. Cancer Res. 2017 Aug 15; 2017 Jun 19. PMID: 28630052.
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T. J Clin Invest. 2017 Jun 1; 2017 May 8. PMID: 28481221.
Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, Yang H, Weissman JS, Loh ML, Müschen M, Tasian SK, Bassik MC, Kampmann M, Pufall MA. Blood. 2017 Jun 1; 2017 Apr 19. PMID: 28424165.
Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.Katerndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Müschen M, Kornblau SM, Farrar MA. Nat Immunol. 2017 Jun; 2017 Apr 3. PMID: 28369050.
BCL6 promotes glioma and serves as a therapeutic target.Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE, Doan N, Said JW, Yong WH, Watkins A, Yang H, Ding LW, Jiang YY, Tyner JW, Ching J, Kovalik JP, Madan V, Chan SL, Müschen M, Breunig JJ, Lin DC, Koeffler HP. Proc Natl Acad Sci U S A. 2017 Apr 11; 2017 Mar 29. PMID: 28356518.
Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1(+) pre-B ALL.Schjerven H, Ayongaba EF, Aghajanirefah A, McLaughlin J, Cheng D, Geng H, Boyd JR, Eggesbø LM, Lindeman I, Heath JL, Park E, Witte ON, Smale ST, Frietze S, Müschen M. J Exp Med. 2017 Mar 6; 2017 Feb 11. PMID: 28190001.
Ibrutinib inhibits pre-BCR(+) B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE, Burger JA. Blood. 2017 Mar 2; 2016 Dec 28. PMID: 28031181.
Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.McCracken AN, McMonigle RJ, Tessier J, Fransson R, Perryman MS, Chen B, Keebaugh A, Selwan E, Barr SA, Kim SM, Roy SG, Liu G, Fallegger D, Sernissi L, Brandt C, Moitessier N, Snider AJ, Clare S, Müschen M, Huwiler A, Kleinman MT, Hanessian S, Edinger AL. Leukemia. 2017 Mar; 2016 Aug 30. PMID: 27573555.
Metabolic gatekeeper function of B-lymphoid transcription factors.Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M. Nature. 2017 Feb 23; 2017 Feb 13. PMID: 28192788.
Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures.Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG. Mol Syst Biol. 2017 Feb 15; 2017 Feb 15. PMID: 28202506.
Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors.Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N. Cell Rep. 2017 Feb 14. PMID: 28199841.
Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, Müschen M, Peled A, Davis RE, Konopleva M, Burger JA. Br J Haematol. 2016 Aug; 2016 Apr 12. PMID: 27071778.
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. Cancer Cell. 2016 Jul 11; 2016 Jul 11. PMID: 27479034.
Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M. Nature. 2016 Jun 2; 2016 Mar 9. PMID: 26958840.
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA. Leukemia. 2016 Jun; 2016 Feb 5. PMID: 26847027.
Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia.Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne KJ, Dovat S. Leukemia. 2016 Jun; 2015 Dec 7. PMID: 26639180.
BCOR regulates myeloid cell proliferation and differentiation.Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP. Leukemia. 2016 May; 2016 Feb 5. PMID: 26847029.
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Blood. 2016 Apr 28; 2016 Feb 10. PMID: 26864341.
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. Cancer Cell. 2016 Apr 11. PMID: 27070704.
Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.Sun H, Lin DC, Guo X, Kharabi Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP. Oncotarget. 2016 Apr 5. PMID: 26934650.
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. Nat Med. 2016 Apr; 2016 Mar 14. PMID: 26974310.
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. Cell Rep. 2015 Dec 29; 2015 Dec 17. PMID: 26711339.
Infection and the Perils of B-cell Activation.Greaves M, Müschen M. Cancer Discov. 2015 Dec. PMID: 26637659.
MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. Blood. 2015 Nov 5; 2015 Aug 31. PMID: 26324703.
Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, Schjerven H, Muschen M, Payne KJ, Dovat S. Blood. 2015 Oct 8; 2015 Jul 28. PMID: 26219304.
HSP90 inhibitors decrease AID levels and activity in mice and in human cells.Montamat-Sicotte D, Litzler LC, Abreu C, Safavi S, Zahn A, Orthwein A, Müschen M, Oppezzo P, Muñoz DP, Di Noia JM. Eur J Immunol. 2015 Aug; 2015 May 18. PMID: 25912253.
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Cancer Cell. 2015 Jul 13; 2015 Jun 11. PMID: 26073130.
Infectious origins of childhood leukemia.Swaminathan S, Müschen M. Oncotarget. 2015 Jul 10. PMID: 26196452.
Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia.Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M. Nat Immunol. 2015 Jul; 2015 May 18. PMID: 25985233.
Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.Müschen M. Blood. 2015 Jun 11; 2015 Apr 15. PMID: 25878119.
Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M. Nature. 2015 May 21; 2015 Mar 23. PMID: 25799995.
Ph+ ALL: drawing strength from a benign past.Müschen M. Blood. 2015 May 7. PMID: 25953975.
YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway.Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. J Hematol Oncol. 2015 Apr 22; 2015 Apr 22. PMID: 25895498.
Human lymphoid translocation fragile zones are hypomethylated and have accessible chromatin.Lu Z, Lieber MR, Tsai AG, Pardo CE, Müschen M, Kladde MP, Hsieh CL. Mol Cell Biol. 2015 Apr; 2015 Jan 26. PMID: 25624348.
Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia.Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. Nat Commun. 2015 Mar 10; 2015 Mar 10. PMID: 25753524.
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M. Cancer Cell. 2015 Mar 9. PMID: 25759025.
Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia.Buchner M, Swaminathan S, Chen Z, Müschen M. Immunol Rev. 2015 Jan. PMID: 25510278.